Harvard Bioscience, Inc.
HBIO · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | -12.71 | -0.10 |
| FCF Yield | 12.83% | 9.91% | 1.55% | -1.28% |
| EV / EBITDA | 358.28 | -1.32 | 41.29 | -87.06 |
| Quality | ||||
| ROIC | -1.32% | -64.51% | 0.00% | -1.77% |
| Gross Margin | 50.71% | 55.96% | 57.06% | 58.10% |
| Cash Conversion Ratio | -0.67 | -1.21 | -0.06 | 95.83 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.09% | -8.03% | -7.25% | -6.00% |
| Free Cash Flow Growth | 1.98% | 73.67% | 195.00% | 17.27% |
| Safety | ||||
| Net Debt / EBITDA | 231.43 | -0.81 | 12.61 | -22.59 |
| Interest Coverage | -1.04 | -49.97 | 0.01 | -2.19 |
| Efficiency | ||||
| Inventory Turnover | 0.45 | 0.42 | 0.45 | 0.35 |
| Cash Conversion Cycle | 209.09 | 224.71 | 212.02 | 255.02 |